Journal of Gastric Cancer最新文献_第4页

Advancing Systemic Therapy in Gastric Cancer: Key Updates From the Korean Practice Guidelines for Gastric Cancer 2024. 推进胃癌的全身治疗：韩国胃癌实践指南2024的关键更新。

IF 3.2 4区医学

Journal of Gastric Cancer Pub Date : 2025-01-01 DOI: 10.5230/jgc.2025.25.e6

Min-Hee Ryu, Keun Won Ryu

引用次数: 0

Conversion Therapy for Stage IV Gastric Cancer: Report From the Expert Consensus Meeting at KINGCA WEEK 2024. IV期胃癌的转化治疗：来自KINGCA WEEK 2024专家共识会议的报告

IF 3.2 4区医学

Journal of Gastric Cancer Pub Date : 2025-01-01 DOI: 10.5230/jgc.2025.25.e9

Tae-Han Kim, Ichiro Uyama, Sun Young Rha, Maria Bencivenga, Jiyeong An, Lucjan Wyrwicz, Dong-Hoe Koo, Richard van Hillegersberg, Keun-Wook Lee, Guoxin Li, Takaki Yoshikawa, Brian Badgwell, Sylvie Lorenzen, In-Ho Kim, In-Seob Lee, Hye-Sook Han, Hur Hoon

{"title":"Conversion Therapy for Stage IV Gastric Cancer: Report From the Expert Consensus Meeting at KINGCA WEEK 2024.","authors":"Tae-Han Kim, Ichiro Uyama, Sun Young Rha, Maria Bencivenga, Jiyeong An, Lucjan Wyrwicz, Dong-Hoe Koo, Richard van Hillegersberg, Keun-Wook Lee, Guoxin Li, Takaki Yoshikawa, Brian Badgwell, Sylvie Lorenzen, In-Ho Kim, In-Seob Lee, Hye-Sook Han, Hur Hoon","doi":"10.5230/jgc.2025.25.e9","DOIUrl":"10.5230/jgc.2025.25.e9","url":null,"abstract":"Conversion therapy is a treatment strategy that shifts from palliative systemic therapy to curative surgical treatment for primary and/or metastatic stage IV gastric cancer (GC). To address its clinical statements, the Korean Gastric Cancer Association aims to present a consensus on conversion therapy among experts attending KINGCA WEEK 2024. The KINGCA Scientific Committee and Development Working Group for Korean Practice Guidelines prepared preformulated topics and 9 clinical statements for conversion therapy. The Delphi method was applied to a panel of 17 experts for consensus and opinions. The final comments were announced after the statement presentation and discussed during the consensus meeting session of KINGCA WEEK 2024. Most experts agreed that conversion therapy provides a survival benefit for selected patients who respond to systemic therapy and undergo R0 resection (88.3%). Patients with limited metastases were considered good candidates (94.2%). The optimal timing was based on the response to systemic therapy (70.6%). The regimen was recommended to be individualized (100%) and the duration to be at least 6 months (88.3%). A minimally invasive approach (82.3%) and D2 lymph node dissection (82.4%) were considered for surgery. However, resection for metastases with a complete clinical response after systemic therapy was not advocated (41.2%). All experts agreed on the need for large-scale randomized-controlled trials for further evidence (100%). Recent advancements in treatment may facilitate radical surgery for patients with stage IV GC. Further evidence is warranted to establish the safety and efficacy of conversion therapy.","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"25 1","pages":"133-152"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739646/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143017117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management Strategy of Non-curative ESD in Gastric Cancer: Curative Criteria, and the Critical Building Block for Determining Beyond It. 胃癌非治愈性ESD的管理策略：治愈标准，以及确定超越它的关键构建块。

IF 3.2 4区医学

Journal of Gastric Cancer Pub Date : 2025-01-01 DOI: 10.5230/jgc.2025.25.e5

Hyuk Lee

{"title":"Management Strategy of Non-curative ESD in Gastric Cancer: Curative Criteria, and the Critical Building Block for Determining Beyond It.","authors":"Hyuk Lee","doi":"10.5230/jgc.2025.25.e5","DOIUrl":"10.5230/jgc.2025.25.e5","url":null,"abstract":"Endoscopic submucosal dissection is performed in cases of early gastric cancer, where the risk of lymph node metastasis (LNM) is expected to be negligible, and 12%-21% of these patients are deemed to have undergone non-curative resections based on pathological criteria. In such cases, decisions regarding additional treatments must be made to maximize curability, depending on the anticipated LNM risk. Well-established risk factors for LNM include lymphatic invasion, vascular invasion, deep submucosal invasion, positive vertical margins, and larger tumor size. When pathological factors associated with a clear LNM risk, such as lymphatic or deep submucosal invasion, are present, additional gastrectomy with lymph node dissection should be considered. Conversely, in cases involving only a positive horizontal margin, additional endoscopic treatment may be an effective therapeutic option as opposed to gastrectomy because of the negligible risk of LNM despite the potential risk of residual tumors. Endoscopic resection is particularly advantageous for determining complete resection. In addition to pathological curability, patient-specific factors, such as age and comorbidities, must be considered. Several retrospective cohort studies have shown that the cause of mortality among patients placed only on observation without additional treatment after non-curative resection is generally related to underlying conditions irrelevant to gastric cancer. Thus, it is crucial to assess both GC-specific mortality and all-cause mortality to finalize treatment decisions that help minimize such mortality. Therefore, new treatment algorithms that integrate pathological curability with patient-specific factors must be developed.","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"25 1","pages":"210-227"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739647/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143016743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PD-L1 as a Biomarker in Gastric Cancer Immunotherapy. PD-L1作为胃癌免疫治疗的生物标志物。

IF 3.2 4区医学

Journal of Gastric Cancer Pub Date : 2025-01-01 DOI: 10.5230/jgc.2025.25.e4

Yunjoo Cho, Soomin Ahn, Kyoung-Mee Kim

{"title":"PD-L1 as a Biomarker in Gastric Cancer Immunotherapy.","authors":"Yunjoo Cho, Soomin Ahn, Kyoung-Mee Kim","doi":"10.5230/jgc.2025.25.e4","DOIUrl":"10.5230/jgc.2025.25.e4","url":null,"abstract":"Combining chemotherapy with immune checkpoint inhibitors (ICIs) that target the programmed death-1 (PD-1) protein has been shown to be a clinically effective first-line treatment for human epidermal growth factor receptor 2 (HER2)-negative and -positive advanced or metastatic gastric cancer (GC). Currently, PD-1 inhibitors combined with chemotherapy are the standard treatment for patients with HER2-negative/positive locally advanced or metastatic GC. Programmed death-ligand 1 (PD-L1) expression, as assessed using immunohistochemistry (IHC), is a crucial biomarker for predicting response to anti-PD-1/PD-L1 agents in various solid tumors, including GC. In GC, the PD-L1 IHC test serves as a companion or complementary diagnostic test for immunotherapy, and an accurate interpretation of PD-L1 status is essential for selecting patients who may benefit from immunotherapy. However, PD-L1 IHC testing presents several challenges that limit its reliability as a biomarker for immunotherapy. In this review, we provide an overview of the current practices of immunotherapy and PD-L1 testing in GC. In addition, we discuss the clinical challenges associated with PD-L1 testing and its future use as a biomarker for immunotherapy. Finally, we present prospective biomarkers currently under investigation as alternative predictors of immunotherapy response in GC.","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"25 1","pages":"177-191"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739645/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143017012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Updated Review of Proximal Gastrectomy for Gastric Cancer or Cancer of the Gastroesophageal Junction. 近端胃切除术治疗胃癌或胃食管交界处癌的最新进展。

IF 3.2 4区医学

Journal of Gastric Cancer Pub Date : 2025-01-01 DOI: 10.5230/jgc.2025.25.e12

Tomoyuki Irino, Manabu Ohashi, Masaru Hayami, Rie Makuuchi, Motonari Ri, Takeshi Sano, Toshiharu Yamaguchi, Souya Nunobe

{"title":"Updated Review of Proximal Gastrectomy for Gastric Cancer or Cancer of the Gastroesophageal Junction.","authors":"Tomoyuki Irino, Manabu Ohashi, Masaru Hayami, Rie Makuuchi, Motonari Ri, Takeshi Sano, Toshiharu Yamaguchi, Souya Nunobe","doi":"10.5230/jgc.2025.25.e12","DOIUrl":"10.5230/jgc.2025.25.e12","url":null,"abstract":"Proximal gastrectomy (PG) has reemerged as a viable surgical option for managing proximal gastric cancer and gastroesophageal junction cancer, particularly for early-stage tumors, offering potential advantages over total gastrectomy (TG). This review examines the evolution of PG, emphasizing surgical techniques and outcomes. Although PG was initially abandoned due to postoperative complications such as reflux esophagitis, advances in reconstruction methods, such as the double-flap technique and double-tract reconstruction, have significantly improved patient quality of life and reduced complications. Modern techniques focus on preserving gastric function, enhancing postoperative nutritional status, and minimizing morbidity, especially compared to TG. However, debates persist regarding the optimal extent of lymphadenectomy, oncological safety, and the risk of metachronous gastric cancer after surgery. Various international guidelines support PG for specific cases, particularly where lymph node involvement is limited, and functional preservation is prioritized. Despite promising survival and quality-of-life outcomes, certain risks, such as anastomotic stenosis and metachronous cancer, remain. The role of PG in treating cancer of the gastroesophageal junction continues to be investigated, with ongoing studies further clarifying its effectiveness. The evolving techniques and increased focus on patient-centered outcomes suggest a renewed role of PG in the surgical management of gastric cancer.","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"25 1","pages":"228-246"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739649/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143017016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Function Preserving Gastrectomy and Quality of Life. 保功能胃切除术与生活质量。

IF 3.2 4区医学

Journal of Gastric Cancer Pub Date : 2025-01-01 DOI: 10.5230/jgc.2025.25.e7

Jeesun Kim, Hyuk-Joon Lee

{"title":"Function Preserving Gastrectomy and Quality of Life.","authors":"Jeesun Kim, Hyuk-Joon Lee","doi":"10.5230/jgc.2025.25.e7","DOIUrl":"10.5230/jgc.2025.25.e7","url":null,"abstract":"Advances in gastric cancer screening have enabled earlier detection, shifting the focus of treatment toward preserving patients' quality of life (QoL). Function-preserving gastrectomy (FPG), including pylorus-preserving gastrectomy, proximal gastrectomy, and sentinel node navigation surgery, represents a paradigm shift in the surgical management of early gastric cancer. These techniques aim to balance oncological safety with the preservation of gastric function, mitigating postgastrectomy syndromes such as dumping syndrome, bile reflux, and nutritional deficiencies. QoL assessment tools, including EORTC QLQ-STO22, KOQUSS-40, and PGSAS-45, have become integral for evaluating patient-reported outcomes, providing insights into physical, emotional, and functional recovery. Although current evidence underscores the benefits of FPG, most studies are limited to East Asia, highlighting the need for multinational trials to validate these findings globally. FPG has demonstrated comparable short- and long-term oncological outcomes to conventional gastrectomy. Enhanced nutritional recovery and reduced gastrointestinal sequelae make FPG increasingly attractive. However, its widespread adoption is challenged by technical complexity, resource intensity, and the need for adequate surgical experience. The integration of advanced technologies, such as robotic surgery and artificial intelligence, coupled with personalized approaches, is expected to further optimize FPG outcomes. This review underscores the critical role of standardized QoL assessments, collaborative research, and technological innovations in advancing FPG as a cornerstone of patient-centered gastric cancer care.","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"25 1","pages":"247-260"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739640/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143015655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oxyntic Gland Neoplasms - From Adenoma to Advanced Gastric Cancer: A Review of 29 Cases. 卵巢腺瘤--从腺瘤到晚期胃癌：29 例病例回顾。

IF 3.2 4区医学

Journal of Gastric Cancer Pub Date : 2024-10-01 DOI: 10.5230/jgc.2024.24.e30

Gi Hwan Kim, Jun Su Lee, Jeong Hoon Lee, Young Soo Park

{"title":"Oxyntic Gland Neoplasms - From Adenoma to Advanced Gastric Cancer: A Review of 29 Cases.","authors":"Gi Hwan Kim, Jun Su Lee, Jeong Hoon Lee, Young Soo Park","doi":"10.5230/jgc.2024.24.e30","DOIUrl":"10.5230/jgc.2024.24.e30","url":null,"abstract":"Purpose: Oxyntic gland neoplasm (OGN) is a rare condition that can be classified as oxyntic gland adenoma (OGA) or gastric adenocarcinoma of fundic-gland type (GA-FG). GA-FG primarily presents as early gastric cancer, with only a few reported cases of advanced gastric cancer (AGC). We aimed to investigate the clinicopathological features of OGN and describe an aggressive variant.Materials and methods: We investigated a total of 29 cases, including a patient with double primary cases, diagnosed with OGN or differentiated-type adenocarcinoma with GA-FG morphology, between November 2016 and April 2022. We analyzed 54 pathological specimens and reviewed their clinicopathological, endoscopic, and histological features. The lesions were reclassified as OGA or GA-FG, and immunohistochemical (IHC) staining for MUC-5AC and MUC-6 was performed on available resected GA-FG cases.Results: The median patient age was 65 years and males accounted for 58.6% of patients. Most cases occurred in the body horizontally (69.0%) and on the greater curvature side cross-sectionally (48.3%). Endoscopically, type 0-IIa (41.4%) and a subepithelial tumor-like appearance (24.1%) were the most common findings. Histologically, there were 8 cases of OGA (27.6%) and 21 cases of GA-FG (72.4%). In GA-FG, MUC-6 was positive in 13 cases (81.3%), whereas MUC-5AC was positive in 8 cases (50.0%). Three cases presented as AGCs.Conclusions: Although OGNs are generally considered low-grade, they can present as AGCs and may exhibit features of lymphovascular or perineural invasion. Recognizing the clinicopathological features and accurately diagnosing OGN are important for providing adequate treatment.","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"24 4","pages":"378-390"},"PeriodicalIF":3.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11471317/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142395605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Erratum: Real-World Application of Artificial Intelligence for Detecting Pathologic Gastric Atypia and Neoplastic Lesions. 勘误：人工智能在检测病理性胃不典型性和肿瘤病变中的实际应用。

IF 3.2 4区医学

Journal of Gastric Cancer Pub Date : 2024-10-01 DOI: 10.5230/jgc.2024.24.e33

Young Hoon Chang, Cheol Min Shin, Hae Dong Lee, Jinbae Park, Jiwoon Jeon, Soo-Jeong Cho, Seung Joo Kang, Jae-Yong Chung, Yu Kyung Jun, Yonghoon Choi, Hyuk Yoon, Young Soo Park, Nayoung Kim, Dong Ho Lee

引用次数: 0

Reply: Comment on The Necessity of Guidance: Optimizing Adjuvant Therapy for Stage II/III MSI-H Gastric Cancer Through the Interplay of Evidence, Clinical Judgment, and Patient Preferences. 答复：关于《指导的必要性》的评论：通过证据、临床判断和患者偏好的相互作用，优化 II/III 期 MSI-H 胃癌的辅助治疗。

IF 3.2 4区医学

Journal of Gastric Cancer Pub Date : 2024-10-01 DOI: 10.5230/jgc.2024.24.e40

In-Ho Kim, Wonyoung Choi, Hye Sook Han

引用次数: 0

Erratum: Textbook Outcome of Delta-Shaped Anastomosis in Minimally Invasive Distal Gastrectomy for Gastric Cancer in 4,505 Consecutive Patients. 勘误：4505 例胃癌微创远端胃切除术中 Delta 型吻合术的教科书式结果。

IF 3.2 4区医学

Journal of Gastric Cancer Pub Date : 2024-10-01 DOI: 10.5230/jgc.2024.24.e31

Seul-Gi Oh, Suin Lee, Ba Ool Seong, Chang Seok Ko, Sa-Hong Min, Chung Sik Gong, Beom Su Kim, Moon-Won Yoo, Jeong Hwan Yook, In-Seob Lee

引用次数: 0